Table 3.

Association Between Incident Atrial Fibrillation and Subsequent Risk of Death Among Adults With Chronic Kidney Disease in a Parallel Matched Cohort Study Design (n=55 409)

	Hazard Ratio (95% CI)
Unadjusted	1.48 (1.41 to 1.54)
Adjusted for age, sex, and race	1.34 (1.28 to 1.40)
Adjusted for age, sex, race, socioeconomic characteristics, comorbid conditions, systolic blood pressure, eGFR, proteinuria, and hemoglobin level*	1.37 (1.28 to 1.40)
Adjusted for age, sex, race, socioeconomic characteristics, comorbid conditions, systolic blood pressure, eGFR, proteinuria, hemoglobin level, and medication use*	1.41(1.32 to 1.49)

ACE indicates angiotensin‐converting enzyme; ARB, angiotensin receptor blockers; eGFR, estimated glomerular filtration rate.

^*Included age, sex, race, education, income level, diabetes mellitus, hypertension, coronary heart disease, baseline ischemic stroke, baseline transient ischemic attack, heart failure, peripheral arterial disease, dyslipidemia, chronic lung disease, chronic liver disease, systolic blood pressure, eGFR, proteinuria, and hemoglobin.

^*Included age, sex, race, education, income level, diabetes mellitus, hypertension, coronary heart disease, baseline ischemic stroke, baseline transient ischemic attack, heart failure, peripheral arterial disease, dyslipidemia, chronic lung disease, chronic liver disease, systolic blood pressure, eGFR, proteinuria, hemoglobin, and baseline medication use (beta blockers, ACE inhibitors or ARBs, calcium channel blockers, diuretics, statins, other lipid‐lowering agents, warfarin, antiplatelet agents).